NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free MLTX Stock Alerts $42.43 -0.82 (-1.90%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$41.80▼$43.6050-Day Range$41.02▼$62.5052-Week Range$19.80▼$64.98Volume273,356 shsAverage Volume462,279 shsMarket Capitalization$2.71 billionP/E RatioN/ADividend YieldN/APrice Target$74.46 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MoonLake Immunotherapeutics alerts: Email Address MoonLake Immunotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside76.5% Upside$74.46 Price TargetShort InterestBearish16.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 6 Articles This WeekInsider TradingSelling Shares$9.49 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.11) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 starsMedical Sector452nd out of 909 stocksPharmaceutical Preparations Industry203rd out of 423 stocks 4.4 Analyst's Opinion Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMoonLake Immunotherapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.21% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently increased by 9.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLTX. Previous Next 2.6 News and Social Media Coverage News SentimentMoonLake Immunotherapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MoonLake Immunotherapeutics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for MLTX on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,490,674.00 in company stock.Percentage Held by Insiders15.27% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.11) to ($1.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -55.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -55.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 5.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Read More MLTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLTX Stock News HeadlinesApril 24, 2024 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives "Buy" Rating from HC WainwrightApril 23, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics: A Promising Outlook with Sonelokimab’s Potential in the HS MarketApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for SonelokimabApril 11, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel OptimismApril 10, 2024 | globenewswire.comMoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditionsApril 10, 2024 | businesswire.comMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsApril 2, 2024 | msn.comGoldman starts MoonLake at neutral, cites lead drug potentialApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 25, 2024 | finance.yahoo.comMLTX Aug 2024 80.000 callMarch 12, 2024 | finance.yahoo.comMLTX May 2024 60.000 callMarch 12, 2024 | finance.yahoo.comMLTX Apr 2024 40.000 putMarch 11, 2024 | marketwatch.comMoonLake Immunotherapeutics Shares Rise Premarket After Pipeline UpdateMarch 11, 2024 | msn.comWhy Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?March 11, 2024 | realmoney.thestreet.comMoonLake price target raised to $100 from $75 at H.C. WainwrightMarch 10, 2024 | globenewswire.comMoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical and Regulatory AdvancesMarch 4, 2024 | globenewswire.comMoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024March 1, 2024 | finance.yahoo.comInsider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)February 29, 2024 | globenewswire.comMoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10February 28, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics: A Promising Buy on Streamlined Clinical Progress and Regulatory SynergyFebruary 26, 2024 | globenewswire.comMoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)February 25, 2024 | seekingalpha.comMoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3February 22, 2024 | benzinga.comMoonLake Stock (NASDAQ:MLTX) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comMoonLake Stock (NASDAQ:MLTX), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comInsider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake ImmunotherapeuticsFebruary 17, 2024 | finance.yahoo.comMLTX Mar 2024 80.000 callSee More Headlines Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/24/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MLTX CUSIPN/A CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$74.46 High Stock Price Target$100.00 Low Stock Price Target$56.00 Potential Upside/Downside+75.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-9.22% Return on Assets-9.00% Debt Debt-to-Equity RatioN/A Current Ratio51.59 Quick Ratio51.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.15 per share Price / Book5.21Miscellaneous Outstanding Shares63,890,000Free Float54,131,000Market Cap$2.71 billion OptionableOptionable Beta1.20 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Jorge Santos da Silva (Age 46)Co-Founder, CEO & Director Comp: $1.11MDr. Kristian Reich (Age 58)Co-Founder & Chief Scientific Officer Comp: $1.2MMr. Matthias Bodenstedt (Age 36)Chief Financial Officer Comp: $588.25kMr. Oliver DaltropChief Technical OfficerNicolas MosimannGeneral CounselLuciana MarquesDirector of HR, People & CultureMs. Nuala BrennanChief Clinical Development OfficerMore ExecutivesKey CompetitorsACADIA PharmaceuticalsNASDAQ:ACADMorphoSysNASDAQ:MOREvotecNASDAQ:EVOSummit TherapeuticsNASDAQ:SMMTIDEAYA BiosciencesNASDAQ:IDYAView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 2,067 shares on 3/22/2024Ownership: 0.010%Wellington Management Group LLPSold 166,195 shares on 3/5/2024Ownership: 0.412%Da Silva Jorge SantosSold 4,740 sharesTotal: $264,918.60 ($55.89/share)Da Silva Jorge SantosSold 62,810 sharesTotal: $3.45 M ($55.00/share)Kristian ReichSold 29,431 sharesTotal: $1.62 M ($55.00/share)View All Insider TransactionsView All Institutional Transactions MLTX Stock Analysis - Frequently Asked Questions Should I buy or sell MoonLake Immunotherapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MLTX shares. View MLTX analyst ratings or view top-rated stocks. What is MoonLake Immunotherapeutics' stock price target for 2024? 12 Wall Street research analysts have issued 1-year price objectives for MoonLake Immunotherapeutics' stock. Their MLTX share price targets range from $56.00 to $100.00. On average, they predict the company's share price to reach $74.46 in the next year. This suggests a possible upside of 76.5% from the stock's current price. View analysts price targets for MLTX or view top-rated stocks among Wall Street analysts. How have MLTX shares performed in 2024? MoonLake Immunotherapeutics' stock was trading at $60.39 at the beginning of the year. Since then, MLTX stock has decreased by 30.1% and is now trading at $42.19. View the best growth stocks for 2024 here. When is MoonLake Immunotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our MLTX earnings forecast. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) posted its quarterly earnings data on Thursday, February, 29th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.11. What ETFs hold MoonLake Immunotherapeutics' stock? ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Harbor Health Care ETF (MEDI), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) and Goldman Sachs Future Health Care Equity ETF (GDOC).First Trust Nasdaq Pharmaceuticals ETF (FTXH). How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLTX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
